Literature DB >> 32214521

Spontaneous Ejaculation Induced with Atomoxetine.

Ferhat Yaylacı1, Begüm Şahbudak1, Önder Küçük1.   

Abstract

Attention Deficit-Hyperactivity Disorder is one of the most common psychiatric disorders of childhood, characterized by attention deficit, hyperactivity and impulsivity. The most effective treatment in ADHD is drug treatment. Stimulant and nonstimulant drug treatments are preferentially used. Atomoxetine is one of the nonstimulant treatments. Although sexual side effects of atomoxetine in adults are reported, there is limited knowledge about sexual side effects in children and adolescents. In this case report, we aimed to describe an adolescent 16-year old with spontaneous ejaculation, a rare sexual side effect, that started at the third day of the treatment and ended by discontinuing atomoxetine.
Copyright © 1964–2020 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  adolescent; atomoxetine; sexual side effect; spontaneous ejaculation

Mesh：

Substances：

Year:  2020        PMID： 32214521      PMCID： PMC7093725     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


  17 in total

1.  Reboxetine-induced spontaneous ejaculation.

Authors:  R O'Flynn; A Michael
Journal:  Br J Psychiatry       Date:  2000-12       Impact factor: 9.319

2.  Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors.

Authors:  Ingrid Oosterhuis; Léon Heijting; Eugène van Puijenbroek
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

3.  An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.

Authors:  T Spencer; J Biederman; J Heiligenstein; T Wilens; D Faries; J Prince; S V Faraone; J Rea; J Witcher; S Zervas
Journal:  J Child Adolesc Psychopharmacol       Date:  2001       Impact factor: 2.576

4.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Authors:  David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

5.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Authors:  D Michelson; D Faries; J Wernicke; D Kelsey; K Kendrick; F R Sallee; T Spencer
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

6.  Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.

Authors:  Enver Yusuf Sivrioglu; Veli Cihat Topaloglu; Asli Sarandol; Cengiz Akkaya; Salih Saygin Eker; Selcuk Kirli
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-11-22       Impact factor: 5.067

Review 7.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

8.  Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Authors:  Douglas K Kelsey; Calvin R Sumner; Charles D Casat; Daniel L Coury; Humberto Quintana; Keith E Saylor; Virginia K Sutton; Jill Gonzales; Sandra K Malcolm; Kory J Schuh; Albert J Allen
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

Review 9.  Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Joshua Caballero; Milap C Nahata
Journal:  Clin Ther       Date:  2003-12       Impact factor: 3.393

Review 10.  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Steven Pliszka
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-07       Impact factor: 8.829
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.